Value of MRI as a surrogate marker for PML in natalizumab long-term therapy

J Neurol. 2012 Aug;259(8):1732-3. doi: 10.1007/s00415-012-6426-5.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Biomarkers
  • Female
  • Humans
  • Leukoencephalopathy, Progressive Multifocal / chemically induced*
  • Leukoencephalopathy, Progressive Multifocal / diagnosis*
  • Leukoencephalopathy, Progressive Multifocal / physiopathology
  • Magnetic Resonance Imaging*
  • Natalizumab
  • Time Factors

Substances

  • Antibodies, Monoclonal, Humanized
  • Biomarkers
  • Natalizumab